Cutia Therapeutics (HK:2487)
:2487
Want to see HK:2487 full AI Analyst Report?
Top Page
Cutia Therapeutics
(2487)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$3.50
▼(-23.75% Downside)
Action:Reiterated
Date:04/28/26
The score is primarily constrained by heavy operating losses and continued cash burn, despite improving revenue growth and solid gross margins. Technical signals are neutral-to-weak with the stock trading below key longer-term moving averages, and valuation is limited by negative earnings and no dividend support.
Positive Factors
Revenue Growth Acceleration
A meaningful acceleration in top-line growth (30.8% in 2025) indicates stronger product adoption or market traction versus 2024. Sustained revenue expansion improves the odds of operating leverage, supports future margin recovery, and lengthens runway for scaling core operations.
Negative Factors
Very Large Operating Losses
Operating margins near -90% show the company is still in heavy investment mode and far from break-even. Such persistent operating losses erode capital, delay self-sufficiency, and mean profitability depends on sustained revenue expansion and major cost structure improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Acceleration
A meaningful acceleration in top-line growth (30.8% in 2025) indicates stronger product adoption or market traction versus 2024. Sustained revenue expansion improves the odds of operating leverage, supports future margin recovery, and lengthens runway for scaling core operations.
Read all positive factors
Cutia Therapeutics (2487) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.31B
Dividend YieldN/A
Average Volume (3M)399.60K
Price to Earnings (P/E)―
Beta (1Y)1.11
Revenue Growth20.92%
EPS Growth27.49%
CountryHK
Employees333
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.05
Shares Outstanding364,730,870
10 Day Avg. Volume272,590
30 Day Avg. Volume399,603
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.52
Price to Sales (P/S)4.01
P/FCF Ratio-4.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$7.45Price Target Upside62.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.03
Revenue Forecast (FY)HK$588.44M
Cutia Therapeutics Business Overview & Revenue Model
Company Description
Cutia Therapeutics operates as a biopharmaceutical company that develops a dermatology platform for skin and scalp diseases. The company focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation mana...
How the Company Makes Money
null...
Cutia Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
55
Neutral
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 336.15M | 279.62M | 137.62M | 11.37M | 2.04M |
| Gross Profit | 195.79M | 143.46M | 71.01M | 7.94M | 1.61M |
| EBITDA | -277.93M | -430.69M | -1.92B | -535.19M | -309.23M |
| Net Income | -340.19M | -433.81M | -1.96B | -555.84M | -319.58M |
Balance Sheet | |||||
| Total Assets | 1.31B | 1.39B | 1.71B | 1.45B | 1.49B |
| Cash, Cash Equivalents and Short-Term Investments | 789.16M | 876.15M | 1.27B | 1.08B | 1.38B |
| Total Debt | 317.53M | 320.94M | 243.75M | 54.13M | 26.53M |
| Total Liabilities | 405.08M | 418.51M | 357.76M | 2.69B | 2.29B |
| Stockholders Equity | 885.66M | 974.73M | 1.35B | -1.25B | -790.51M |
Cash Flow | |||||
| Free Cash Flow | -302.97M | -468.66M | -437.23M | -371.50M | -185.76M |
| Operating Cash Flow | -290.09M | -442.98M | -381.31M | -236.19M | -159.88M |
| Investing Cash Flow | -20.28M | 316.07M | -203.58M | 462.06M | -410.65M |
| Financing Cash Flow | 193.03M | 37.84M | 588.32M | -10.25M | 480.76M |
Cutia Therapeutics Technical Analysis
Negative
4.59
Price Trends
4.40
Negative
4.63
Negative
6.21
Negative
Market Momentum
-0.28
Positive
31.64
Neutral
35.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2487, the sentiment is Negative. The current price of 4.59 is above the 20-day moving average (MA) of 3.99, above the 50-day MA of 4.40, and below the 200-day MA of 6.21, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 31.64 is Neutral, neither overbought nor oversold. The STOCH value of 35.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2487.
Cutia Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$1.65B | 25.32 | 43.89% | ― | 150.60% | ― | |
44 Neutral | HK$1.62B | -13.42 | -27.70% | ― | -100.00% | 50.29% | |
43 Neutral | HK$568.36M | -4.34 | 191.92% | ― | -100.00% | 77.06% | |
42 Neutral | HK$1.31B | -3.12 | -41.43% | ― | 20.92% | 27.49% | |
42 Neutral | HK$800.12M | -1.25 | -75.15% | ― | 79.76% | 7.68% | |
41 Neutral | HK$681.22M | -2.86 | -28.13% | ― | -33.80% | 31.52% |
* Healthcare Sector Average
HK:2487
Cutia Therapeutics
3.58
-7.60
-67.98%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
1.92
-0.08
-4.00%
HK:2181
Mabpharm Limited
0.40
-0.10
-20.00%
HK:2257
Sirnaomics Ltd.
5.18
0.50
10.68%
HK:3681
SinoMab Bioscience Ltd.
1.18
-1.40
-54.26%
HK:6628
Transcenta Holding Limited
1.53
-0.15
-8.93%
Cutia Therapeutics Corporate Events
Cutia Wins NMPA Nod for Topical Anesthesia Cream, Expanding China Dermatology Portfolio
May 6, 2026
Cutia Therapeutics has obtained marketing authorization from China’s National Medical Products Administration for CU-30101, a localized topical lidocaine and tetracaine cream for anesthesia procedures. The product demonstrated comparable eff...
Cutia Therapeutics Changes Cayman Share Registrar Name Without Moving Registered Office
Apr 27, 2026
Cutia Therapeutics has announced a change in the name of its principal share registrar, transfer office and registered office service provider in the Cayman Islands from Harneys Fiduciary (Cayman) Limited to Ascentium (Cayman) Limited, effective 1...
Cutia Therapeutics Sets 2026 AGM to Vote on Board, Auditor and Share Mandates
Apr 24, 2026
Cutia Therapeutics has called its annual general meeting for 26 June 2026 in Shanghai, where shareholders will review the audited financial statements for the year ended 31 December 2025 and the accompanying reports from directors and auditors. Th...
Cutia Therapeutics’ Botox Rival Meets Phase III Goals in China
Apr 13, 2026
Cutia Therapeutics has reported the completion of a Phase III clinical trial in China for CU-20101, its botulinum toxin type A injection aimed at treating moderate to severe glabellar lines. The study, which used Botox as the reference product, me...
Cutia Therapeutics Boosts Revenue and Margins as Key Dermatology Products Launch in 2025
Mar 24, 2026
Cutia Therapeutics reported that two key dermatology products, CU-40102 topical finasteride spray and CU-10201 topical 4% minocycline foam, entered commercialization in late October 2025 and generated over RMB100 million in revenue for the year. T...
Cutia Therapeutics Wins China Trial Nod for New Topical Hair-Loss Drug
Mar 16, 2026
Cutia Therapeutics has received clinical trial approval from China’s National Medical Products Administration for its investigational drug CU-40104, a self-developed topical dutasteride formulation for androgenetic alopecia. The product is d...
Cutia Therapeutics Sets March 2026 Board Meeting to Approve 2025 Annual Results
Mar 12, 2026
Cutia Therapeutics has scheduled a board meeting for 24 March 2026 to review and approve the annual results for the year ended 31 December 2025, and to authorize their publication. The board will also consider recommending a final dividend, if any...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.